---
title: "Leqvio (inclisiran), all indications: Safety questions"
description: "Safety questions on Leqvio (inclisiran) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring and Warnings. Questions: When should LDL-C be checked after starting Leqvio? What are the contraindications for Leqvio? Can Leqvio cause allergic reactions? Does Leqvio cause anti-drug antibodies? 2 further questions follow. 6 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/leqvio/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Leqvio (inclisiran), all indications: Safety questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Leqvio](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf)  
Indication pages: [Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia)

## Monitoring

<a id="leqvio-ldl-monitoring"></a>

### When should LDL-C be checked after starting Leqvio?

> “Assess LDL-C when clinically indicated. The LDL-lowering effect of LEQVIO may be measured as 
> early as 30 days after initiation and anytime thereafter without regard to timing of the dose.”

Source: [LEQVIO: Prescribing information, page 2, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=2)

## Warnings

<a id="leqvio-contraindications"></a>

### What are the contraindications for Leqvio?

> “LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the 
> excipients in LEQVIO. Serious hypersensitivity reactions have included anaphylaxis and angioedema [see 
> Adverse Reactions (6.2)].”

Source: [LEQVIO: Prescribing information, page 2, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=2)

<a id="leqvio-allergic-reactions"></a>

### Can Leqvio cause allergic reactions?

> “Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with 
> LEQVIO [see Adverse Reactions (6.2)]. Advise patients on the signs and symptoms of hypersensitivity 
> reactions and instruct patients to seek medical attention promptly.”

Source: [LEQVIO: Prescribing information, page 3, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=3)

> “Hypersensitivity: anaphylaxis, angioedema, rash, pruritus, and urticaria.”

Source: [LEQVIO: Prescribing information, page 4, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=4)

Note: The second passage lists hypersensitivity reactions identified during postmarketing use of Leqvio.

## Safety

<a id="leqvio-antibodies"></a>

### Does Leqvio cause anti-drug antibodies?

> “Samples from 1,830 adult patients in the placebo-controlled clinical trials were tested for ADA [see Clinical 
> Studies (14)]. Confirmed positivity was detected in 33/1,830 (2%) patients prior to receiving LEQVIO and in 
> 90/1,830 (5%) patients during the 18 months of treatment with LEQVIO.”

Source: [LEQVIO: Prescribing information, page 8, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=8)

> “There was no identified clinically significant effect of anti-inclisiran antibodies on pharmacodynamics, safety, 
> or effectiveness of LEQVIO in adults and pediatrics during the placebo-controlled studies. However, the long-
> term consequences of continuing LEQVIO treatment in the presence of anti-inclisiran binding antibodies are 
> unknown.”

Source: [LEQVIO: Prescribing information, page 9, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=9)

<a id="leqvio-cancer-animal-studies"></a>

### Did Leqvio cause cancer in animal studies?

> “In a 2-year carcinogenicity study, Sprague-Dawley rats were administered subcutaneous doses of 40, 95, or 250 
> mg/kg inclisiran once every 28 days (1, 3, or 8 times the MRHD, based on BSA comparison/dose). Inclisiran 
> was not carcinogenic up to the highest dose tested. 
> In a 26-week study in RasH2Tg mice, subcutaneous doses of 300, 600, or 1,500 mg/kg once every 28 days were 
> administered. Inclisiran was not carcinogenic up to the highest dose tested. 
> Inclisiran was not mutagenic or clastogenic in a standard battery of genotoxicity tests, including a bacterial 
> mutagenicity assay, an in vitro chromosome aberration assay using human peripheral lymphocytes, and an in 
> vivo bone marrow micronucleus assay in rats.”

Source: [LEQVIO: Prescribing information, page 9, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=9)

Note: These are nonclinical studies in rats and mice from the Prescribing Information.

<a id="leqvio-qt-interval"></a>

### Does Leqvio prolong the QT interval?

> “At a dose 3 times the maximum recommended dose, inclisiran does not prolong the QT interval to any clinically 
> relevant extent.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

## Related pages
- [Medical information: Leqvio (inclisiran): All indications](https://www.evicenter.com/medical-information/leqvio)
- [Indication](https://www.evicenter.com/medical-information/leqvio/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/leqvio/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/leqvio/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/leqvio/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/leqvio/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/leqvio/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/leqvio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/leqvio/access-and-coverage)
